FEATURE / CONNECTING The cost of a cure CELL AND GENE THERAPIES (CGT) are poised to change health care in the next decade. In 2023, CGTs represented $6 billion in pharmaceutical spending; by 2033, that figure is expected to grow to $70 billion. Starting in 2025, the Food and Drug Administration expects to approve 10 to 15 new CGTs annually. While potentially lifesaving for patients with rare diseases, these novel therapies come with financial, ethical, and operational challenges. From legal reviews to effective contracting to capacity management to staff education, pediatric hospitals must prepare now to offer these therapies. CHA's High-Cost Therapy Work Group recommended forming a committee with hospital representatives who can bridge the gap between manufacturers and patients, manage supply chain and cash flow risks, and operationalize processes to administer CGTs. Explore federal policies that support high-cost therapies at childrenshospitals .org/highcost. 28 CHILDREN'S HOSPITALS TODAY Fall 2024https://www.childrenshospitals.org/highcost https://www.childrenshospitals.org/highcost